APPENDIX 4C - QUARTERLY REPORT Exhibit 1 Appendix 4C - Q4 FY19 Quarterly Cash Flow Report Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve conc

4C - Q4 FY19 Quarterly Cash Flow Report

AUSTRALIA AND SAN FRANCISCO, USA - Wednesday 31 July 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity"

or "the Company"), releases its Appendix 4C Quarterly Cash Flow report and update on company activities for the quarter

ending 30 June 2019 (Q4 FY19).

past quarter saw important milestones achieved as the Company enters into its next phase of development, the most significant

being finalization and reporting of its Phase 1 Clinical Trial for its lead compound PBT434.

completed trial includes data from elderly and healthy volunteers who received repeated doses, and demonstrated that the drug

was safe and well-tolerated, with adverse event rates comparable to placebo. It builds on the data presented in May 2019 at the

American Academy of Neurology Annual Meeting in the US.

exposure to the drug was comparable between elderly and healthy volunteers. This information, along with previous results in the

Phase 1 study, indicate that clinically-tested doses achieve concentrations in the brain that are comparable with other test results.

No serious adverse event or an adverse event that led to discontinuation of the study drug was reported.

findings showed that PBT434 passed the blood-brain barrier and inhibited the alpha-synuclein protein which when aggregated in

the brain is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for treating these

neurodegenerative diseases.

Company launched a new name moving from Prana Biotechnology to Alterity Therapeutics. The name change aligns with the new direction

for the Company and followed a major strategic investment by Life Biosciences. A$11.44M has so far been received as part of this

investment. Shareholders approved a resolution to allow the investment by Life Biosciences and the name change at an Extraordinary

General Meeting on 5th April.

reported a strong cash balance of A$14.4M, up from A$8.9M in Q3 FY19 with the contribution of investment funds.

Geoffrey Kempler, CEO of Alterity, said: "The final quarter of Alterity's financial year has ended on a high note

with the recent completion of the Phase 1 trial for PBT434. The clinical data for the Phase 1 trial was well-received at the American

Academy of Neurology Annual Meeting in Philadelphia, a key audience for Alterity. We thank Life Biosciences for its investment."

enquiries IR@alteritytherapeutics.com

Wilson or Dylan Mark

Alterity Therapeutics Limited

lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological

proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of -synuclein and tau proteins

in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various

forms of atypical Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).

further information please visit the Company's web site at www.alteritytherapeutics.com

press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933

and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use

of such words as "expects," "intends," "hopes," "anticipates," "believes,"

"could," "may," "evidences" and "estimates," and other similar expressions, but

these words are not the exclusive means of identifying such statements.

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described

in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual

Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's

drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's

drug development program, including, but not limited to, PBT434, and any other statements that are not historical facts. Such

statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties

or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components,

including, but not limited to, PBT434, the ability of the Company to procure additional future sources of financing, unexpected

adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to,

PBT434, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual

property or trade secrets, including, but not limited to, the intellectual property relating to PBT434.

forward-looking statement made by us in this press release is based only on information currently available to us and speaks only

as of the date on which it is made. We undertake no obligation to publicly updated any forward-looking statement, whether written

or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

report for entities subject to Listing Rule 4.7B

report for entities subject to Listing Rule 4.7B

31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

report for entities subject to Listing Rule 4.7B

report for entities subject to Listing Rule 4.7B

director's fees and consulting fees at normal commercial rates.

Excludes GST where applicable.

report for entities subject to Listing Rule 4.7B

report for entities subject to Listing Rule 4.7B